Biomerica Inc (BMRA)
Biomerica, Inc. is a healthcare company focused on biomedical technology, with activities spanning the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products used in the detection and treatment of medical conditions. Its diagnostic test kits are designed to analyze samples such as blood, urine, nasal, or fecal specimens and are used in testing for diseases, food intolerances, and other medical issues, including measurements of bacteria, hormones, antibodies, antigens, and related substances. The company markets products for gastrointestinal diseases and food intolerances through physicians’ offices, over-the-counter drugstores, and hospital and clinical laboratory settings. Biomerica is also developing InFoods IBS, a blood-based test intended to help identify foods that may reduce irritable bowel syndrome symptoms, and hp+detect, a diagnostic test for Helicobacter pylori infection. Founded in 1971, the company is headquartered in Irvine, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BMRA
|
$2.12
|
-23.8% Downside
|
Overvalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
October 9, 2026
|
4.5x
|
2.7x
|
12.757 M
|
12.506 M
|
16.6%
|
91.1%
|
-12.2
|
90.6%
|
